- Home
- SGP vs KURA Comparison
SGP vs KURA Comparison
Compare SGP & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | KURA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | 260 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 841.6M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SGP | KURA |
|---|---|---|
| Price | $23.46 | $9.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $45.00 | $25.56 |
| AVG Volume (30 Days) | 49.1K | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $20.15 | $5.45 |
| 52 Week High | $30.56 | $12.49 |
Technical Indicators
Market Signals| Indicator | SGP | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 51.19 |
| Support Level | $20.95 | $8.95 |
| Resistance Level | $26.29 | $9.82 |
| Average True Range (ATR) | 1.47 | 0.43 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 38.44 | 50.34 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.